- Home
- NVCT
NVCT
Nuvectis Pharma Inc.
as 12-20-2024 4:00pm EST
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | FORT LEE |
| Market Cap: | 119.4M | IPO Year: | 2022 |
| Target Price: | $21.00 | AVG Volume (30 days): | 94.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.44 - $12.10 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nuvectis Pharma Inc. (NVCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | NVCT | 10% Owner | Dec 13 '24 | Buy | $4.70 | 17,000 | $79,900.00 | 2,612,000 | |
| Mosseri Marlio Charles | NVCT | 10% Owner | Dec 12 '24 | Buy | $4.67 | 49,121 | $228,941.44 | 2,612,000 | |
| Poradosu Enrique | NVCT | Chief Science & Business Off | Nov 19 '24 | Buy | $4.99 | 2,000 | $9,980.00 | 1,506,319 | |
| BENTSUR RON | NVCT | Chairman & CEO | Nov 15 '24 | Buy | $4.92 | 20,000 | $98,400.00 | 3,266,424 |
Latest Nuvectis Pharma Inc. News
NVCT Breaking Stock News: Dive into NVCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Zacks
a month ago
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
TipRanks
a month ago
Nuvectis Pharma reports data from Phase 1b study of NXP800
Benzinga
a month ago
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
MT Newswires
a month ago
Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage
GlobeNewswire
a month ago
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Zacks
a month ago
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks
a month ago
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Compare NVCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCT Nuvectis Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.